Apilimod for COVID-19: real-time analysis

Download Image

Post

c19early.org

Apilimod for COVID-19

1 study with 141 patients

Serious outcome risk

Apilimod

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Apilimod studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−199%

Mortality (1)−199%

RCTs (1)−199%

Early (1)−199%

00.511.5+

← Apilimod
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Apilimod is an oral, small molecule drug that inhibits the human PIKfyve kinase.


Apr 19 2021	Young et al., NCT04446377	A Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19
Apr 19 2021	199% higher mortality (p=1), 100% higher combined mortality/hospitalization (p=1), and 109% worse recovery (p=0.43). RCT 142 COVID-19 patients showing no significant differences with apilimod treatment.